Skip to main content

Table 1 Age, Gender, Race and Pulmonary Function of study patients

From: The effect of tiotropium therapy on markers of elastin degradation in COPD

PATIENT NUMBER

AGE

GENDER

RACE

STUDY

FVC**

%Pred

FEV1**

%Pred

FEV1/FVC**

%

-1-

61

M

C*

Pre-Tio

1 mo post

2 mo post

77

91

77

47

53

47

46

44

46

-2-

79

F

C*

Pre-Tio

1 mo post

2 mo post

97

96

106

64

72

73

49

56

51

-3-

65

F

AA*

Pre-Tio

1 mo post

2 mo post

106

96

108

74

65

66

54

53

48

-4-

63

F

C*

Pre-Tio

1 mo post

2 mo post

92

107

100

41

52

45

46

48

46

-5-

65

F

H*

Pre-Tio

1 mo post

2 mo post

70

84

84

67

84

82

75

79

78

-6-

65

M

A*

Pre-Tio

1 mo post

2 mo post

56

49

51

49

49

52

66

75

78

-7-

64

M

C*

Pre-Tio

1 mo post

2 mo post

59

69

64

41

47

41

51

51

48

-8-

39

M

C*

Pre-Tio

1 mo post

2 mo post

52

69

62

24

30

29

30

35

38

-9-

57

F

H*

Pre-Tio

1 mo post

2 mo post

93

87

83

55

55

53

47

51

51

-10-

69

M

AA*

Pre-Tio

1 mo post

2 mo post

58

82

109

30

39

54

39

36

38

-11-

66

F

C*

Pre-Tio

1 mo post

2 mo post

97

103

90

62

60

58

49

45

48

-12-

59

M

C*

Pre-Tio

1 mo post

2 mo post

110

91

102

72

69

71

50

57

53

  1. * AA = African-American
  2. C = Caucasian
  3. H = Hispanic
  4. A = Asian
  5. ** FVC%Pred = Forced Vital Capacity % of predicted
  6. FEV-1%Pred = Forced Expiratory Volume in 1 second % of predicted.
  7. FEV-1/FVC% = absolute ratio as percent.